Category: Default

3 Advantages Of Polyclonal Antibodies

Polyclonal antibodies are heterogeneous and complex mixtures of immunoglobulins produced by different B cells, which recognize different epitopes within the same antigen.

These characteristics give polyclonal antibodies some virtues compared to monoclonal ones in certain applications, techniques and / or tests.

In this entry we collect 3 advantages of polyclonal antibodies that make them the reagents of choice in certain situations.

1.- Production

Regarding the production method, polyclonal antibodies have the following advantages over monoclonal ones:

  • Production is much faster, being able to obtain polyclonal antibodies purified and ready for use in just 45 days .
  • The production system is not expensive.
  • The production method is less complex.
  • They can be generated in a wide variety of host animals (You can expand the information in this entry on Species for the production of antibodies, which is better? ).

2.- Sensitivity, Affinity And Robustness

By recognizing multiple epitopes of the same antigen, polyclonal antibodies offer greater sensitivity, affinity, and robustness than monoclonal antibodies:

  • Affinity

Binding to several epitopes makes the affinity for the target higher, and this generally implies faster binding to the antigen, which is a great advantage in assays such as immunoprecipitation that require rapid capture of the protein.

  • Sensitivity

The recognition of multiple epitopes also results in an increase in sensitivity when amplifying the signal, favoring the detection of proteins present in low quantities.

  • Sturdiness

In the case of slight variations in individual epitopes as a consequence of polymorphisms, denaturation or conformational changes, the results obtained with polyclonal antibodies will be more robust due to their ability to bind to different epitopes of the same antigen.

3.- Stability

In general, polyclonal antibodies are more stable than monoclonal antibodies and therefore easier to store because:

  • They better tolerate buffer, pH and temperature changes.
  • Due to the biophysical diversity in terms of charges and hydrophobicity offered by polyclonal antibodies, they present greater stability against phenomena that could lead to precipitation or inactivation in the case of monoclonal antibodies.

In conclusion, the advantages of polyclonal antibodies can be summarized in that they are easier to produce and store, and offer multiple benefits compared to monoclonal antibodies thanks to their ability to recognize various epitopes of the same antigen.


Apoptosis is a programmed cell death mechanism that is induced by a variety of factors that activate cysteine ​​proteases known as caspases, leading the cell to its final death.

The use of antibodies for apoptosis directed against specific proteins of the apoptotic pathway, is an essential tool for studying the role of apoptosis in different experimental models.

In this post we tell you how to identify the best antibodies for apoptosis, as well as other related proteins and ELISA kits. But before we learn a little more about this cell death mechanism.


The correct regulation of apoptosis is fundamental for the proper development of the organs and their homeostasis, as well as a fundamental part of immunity.

It is a normal and essential biological process, for example, for the proper development of organs during embryogenesis or the elimination of abnormal cells such as tumor cells or those damaged by pathogens or toxic stimuli.

However, premature or unscheduled apoptosis can lead to loss of functional cells, which could lead to autoimmune, neurological, or cardiovascular disorders.


The apoptosis or programmed cell death, is by necrosis and autophagy one of the mechanisms that cause cell death. The main difference between these three mechanisms are the morphological changes at the cellular level that take place next to each one of them, as well as the proteins involved in their activation and execution.

In the case of apoptosis, the most characteristic changes in cell morphology are usually cell contraction, chromatin condensation, nuclear fragmentation, and cell rupture with the consequent formation of apoptotic bodies.

The main proteins involved in activating apoptotic pathways are caspases and the p53 protein.


As in so many other areas of study, the use of correctly validated apoptosis antibodies is critical to achieving robust and reproducible results.

Once the protein or proteins of interest for the investigation have been identified, it is convenient to identify and select quality reagents, which have undergone exhaustive validation procedures that guarantee success in a given experimental application.

As an example we bring you one of the proteins that is most frequently analyzed using antibodies for apoptosis: Caspase 9 (CASP9) .

After a search for antibodies to apoptosis and other validated bioreactants (in this case we have focused on reactivity in humans), we obtain the following selection:

ReferenceNameApplications for which it is validated
ProteinsABK1-P2614Recombinant Caspase 9 (CASP9)Positive Control; Immunogen; SDS-PAGE; WB.
ABK1-P2615Recombinant Caspase 9 (CASP9)Positive Control; Immunogen; SDS-PAGE; WB.
ABK1-P2616Recombinant Caspase 9 (CASP9)Positive Control; Immunogen; SDS-PAGE; WB.
AntibodiesABK1-A1599Polyclonal Antibody to Caspase 9 (CASP9)WB; IHC; ICC; IP.
ABK1-A7669Polyclonal Antibody to Caspase 9 (CASP9)WB; IHC; ICC; IP.
ABK1-A1393Polyclonal Antibody to Caspase 9 (CASP9)WB; IHC; ICC; IP.
ELISA kitsABK1-E184ELISA Kit for Caspase 9 (CASP9)Enzyme-linked immunosorbent assay for Antigen Detection.

These antibodies, proteins and ELISA kits are validated for the techniques indicated in each case, ensuring their good performance based on the established procedure.

In case you are interested in other antibodies to apoptosis or any other area of research , do not hesitate to contact us and our team will advise on the best validated antibodies and guaranteed for each case.

A type II implementation-effectiveness hybrid quasi-experimental pilot study of a clinical intervention to re-engage people living with HIV into care, ‘Lost & Found’: an implementation science protocol.

At the McGill University Health Centre (MUHC), 10% of sufferers living with HIV don’t return for care yearly.

Currently, no formal system exists to re-engage out-of-care (OOC) sufferers. Lost & Found, developed utilizing an implementation science method, is an intervention to re-engage OOC sufferers. It relies on current evidence-based interventions and might be tailored to be used by nurses on the MUHC.

The goals of this study are to concurrently assess each implementation and effectiveness of Lost & Found so as to decide the viability of a future multisite stepped-wedge cluster randomised trial.

Lost & Found consists of two core parts: figuring out and contacting OOC sufferers. Based on formative work involving MUHC nurses, and the use of a mixed implementation framework (enhanced Replicating Effective Programs, Tailored Implementation for Chronic Diseases, and Proctor et al.’s implementation outcomes), we are going to adapt the intervention to our clinic.

Adaptations embrace the creation of an OOC threat prediction device, an automated real-time OOC checklist, and prioritization of high-risk OOC sufferers for re-engagement.

Delivery and ongoing adaptation of the intervention will observe a three-pronged implementation technique consisting of

  • selling adaptability;
  • planning, partaking, executing, evaluating, and reflecting cycles; and
  • inner facilitation. T

his 15-month quasi-experimental pilot study adopts a type II implementation-effectiveness hybrid design.

To consider implementation, a convergent parallel mixed-methods method will information the blending of qualitative and quantitative information at time factors all through the study.

In addition, descriptive and pre-post analyses, for every of the implementation and sustainability phases, will inform evaluations of the cumulative effectiveness and sustainability of the Lost & Found intervention.

This study will present preliminary proof for (1) the utility of our chosen implementation methods and (2) the effectiveness of the intervention. Ultimately, this data could also be used to inform future re-engagement efforts utilizing implementation science in different HIV care centres.

In addition, the procedures and measurement instruments developed for this study might be foundational to the event of a multi-site, randomised stepped wedge study that would offer extra strong proof in help of the Lost & Found intervention.

A type II implementation-effectiveness hybrid quasi-experimental pilot study of a clinical intervention to re-engage people living with HIV into care, 'Lost & Found': an implementation science protocol.
A type II implementation-effectiveness hybrid quasi-experimental pilot study of a clinical intervention to re-engage people living with HIV into care, ‘Lost & Found’: an implementation science protocol.

ICI-RS 2019 nocturia assume tank: How can experimental science information us in understanding the pathophysiology of nocturia?

The following is a report on the proceedings of the 2019 International Consultation on Incontinence-Research Society nocturia assume tank (NTT).

The goals of the 2019 NTT had been as follows: (a) to consider the function of urothelium within the pathophysiology of nocturia; (b) to decide whether or not nocturia is a circadian dysfunction; (c) to focus on the function of melatonin in nocturia; (d) to think about ambulatory urodynamic monitoring in evaluating sufferers with nocturia; (e) to discover research of water dealing with in human compartments using heavy water; and (f) to discover whether or not primary science is the important thing to understanding the remedy choices for diminished bladder capability in sufferers with nocturia.

A compendium of discussions of the function of experimental science in understanding the pathophysiology of nocturia is described herein.Translational science will play an rising function in understanding the pathophysiology of nocturia, which can end in improved remedy methods.